myeloid biology

Events

Partner Content

Welcome to the 2nd Tumor Myeloid-Directed Therapies Summit

Identify, Validate, & Clinically Develop Novel Targets to Modulate Myeloid Cells & Overcome Solid Tumor Barriers

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks